| Name | Title | Contact Details |
|---|---|---|
Scott Tambert |
Director of Technology Solutions and Information Security Officer | Profile |
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia
The mission of Mental Health Resources, Inc. is to foster hope, health and recovery for those affected by mental illness.
BioFX Laboratories is a Owings Mills, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Were one of the world’s leading providers of high quality, empty, hard capsules serving global pharmaceutical and dietary supplement markets.
Granite Recovery Centers are the New England drug and alcohol addiction treatment centers you can rely on for recovery. Call 855.712.7784 today to learn more!